🔥🐔 BizChicken 🐔🔥

Companies Similar to Glaukos Corporation

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation logo
Market Cap: High
Employees: High

surgical implants and medical instruments

Integra Life Sciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for neurosurgery, extremity reconstruction, and general surgery. It operates in segments such as Codman Specialty Surgical and Tissue Technologies, offering a range of products including neurosurgery equipment and regenerative technology for wound treatment.

Tags: extremity reconstruction, general surgery, medical instruments, neurosurgery, surgical implants, tissue technologies

Symbol: IART

Recent Price: $22.47

Industry: Medical - Devices

CEO: Mr. Jan De Witte

Sector: Healthcare

Employees: 3946

Address: 1100 Campus Road, Princeton, NJ 08540

Phone: 609 275 0500

Last updated: 2024-12-31

Eyenovia, Inc.

Eyenovia, Inc. logo
Market Cap: Lowest
Employees: Lowest

Optejet

Eyenovia, Inc. is focused on developing therapeutic solutions for ophthalmic conditions using its proprietary microdose array print platform and Optejet delivery system. It targets conditions like progressive myopia, presbyopia, and mydriasis.

Tags: Optejet, microdosing, mydriasis, myopia, ophthalmic, pharmaceuticals, presbyopia, therapeutics

Symbol: EYEN

Recent Price: $0.11

Industry: Biotechnology

CEO: Mr. Michael M. Rowe

Sector: Healthcare

Employees: 57

Address: 295 Madison Avenue, New York, NY 10017

Phone: 917 289 1117

Leadership

  • Charles Mather, Chairman of the Board
  • Ellen Strahlman, MD, MS, Independent Director
  • Sean Ianchulev, MD, MPH, Director
  • Michael Geltzeiler, Independent Director
  • Rachel Jacobson, Independent Director
  • Ram Palanki, PharmD, Independent Director
  • Michael Rowe, Director

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

Sotagliflozin, LX9211

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products, with drugs like Sotagliflozin and LX9211 under development for heart failure, type 1 diabetes, and neuropathic pain.

Tags: biopharmaceutical, drug development, heart failure, neuropathic pain, type 1 diabetes

Symbol: LXRX

Recent Price: $0.72

Industry: Biotechnology

CEO: Dr. Michael Exton Ph.D.

Sector: Healthcare

Employees: 285

Address: 2445 Technology Forest Boulevard, The Woodlands, TX 77381

Phone: 281 863 3000

Leadership

  • Brian Corrigan, Senior Vice President, Regulatory and Quality Assurance
  • Brian Crum, Senior Vice President and General Counsel
  • Lisa DeFrancesco, Vice President, Investor Relations and Corporate Communications
  • Mike Exton, Ph.D., Chief Executive Officer and Director
  • Tom Garner, Senior Vice President and Chief Commercial Officer
  • Craig Granowitz, MD, PhD, Senior Vice President and Chief Medical Officer
  • Alan Main, PhD, Executive Vice President, Innovation and Chemical Sciences
  • Wendy McDermott, Senior Vice President, Human Resources
  • Kristen Alexander, Vice President, Finance and Accounting
  • Phillip Banks, MS, FRS, Vice President, Biostatistics and Data Management
  • Kyle Burt, Vice President, Information Operations
  • Amy Carroll, Ph.D., Vice President, Medical Affairs
  • Melinda Francini, Vice President, Value and Access
  • Desiree Gendron, Vice President, Sales and Training
  • Suma Gopinathan, Ph.D., Vice President, Clinical Development
  • Rachel Martens, Vice President, Partnerships and Corporate Strategy
  • Nicole Moore, Vice President, Legal
  • Tracy Newbold, Vice President, Clinical Operations
  • Godfried Owusu-Ababio, Vice President, Technical Operations
  • Rob Scala, Vice President, Business Planning and Commercial Operations
  • Carrie Siragusa, Vice President, Marketing
  • Dixon Terry, Vice President, Compliance
  • Raymond Debbane, Chairman
  • Philippe J. Amouyal,
  • Samuel L. Barker, PhD,
  • Robert J. Lefkowitz, MD,
  • Christopher J. Sobecki,
  • Diane E. Sullivan,
  • Judith L. Swain, MD,

Last updated: 2024-12-31

Glaukos Corporation

Glaukos Corporation logo
Market Cap: Highest
Employees: Medium

i Stent, i Stent inject, i Stent inject W, i Stent Infinite, i Dose TR

Glaukos Corporation is a medical technology and pharmaceutical company developing therapies for glaucoma, corneal disorders, and retinal diseases. It offers micro-bypass stents and injectable implants intended to improve intraocular treatment.

Tags: corneal disorders, glaucoma treatment, i Dose TR, i Stent, medical technology, ophthalmic, pharmaceutical, retinal diseases

Symbol: GKOS

Recent Price: $149.51

Industry: Medical - Devices

CEO: Mr. Thomas William Burns

Sector: Healthcare

Employees: 907

Address: 229 Avenida Fabricante, San Clemente, CA 92672

Phone: 949 367 9600

Last updated: 2024-12-31

Clearside Biomedical, Inc.

Clearside Biomedical, Inc. logo
Market Cap: Low
Employees: Lowest

XIPERE

Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. They offer treatments such as XIPERE for uveitis macular edema and are developing additional therapies for ocular conditions.

Tags: XIPERE, biopharmaceutical, clinical trials, macular edema, ocular therapies, suprachoroidal injection, uveitis

Symbol: CLSD

Recent Price: $0.99

Industry: Biotechnology

CEO: Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.

Sector: Healthcare

Employees: 30

Address: 900 North Point Parkway, Alpharetta, GA 30005

Phone: 678 270 3631

Last updated: 2024-12-31

EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

EGP-437

Eye Gate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye.

Tags: EGP-437, clinical stage, drug delivery, eye diseases, pharmaceutical, uveitis

Symbol: EYEG

Recent Price: $35.04

Industry: Biotechnology

CEO: Mr. Stephen From

Sector: Healthcare

Employees: 14

Address: 271 Waverley Oaks Rd Ste 108, Waltham, MASSACHUSETTS 02452

Phone: 17817889043

Leadership

  • Paul Chaney, Chairman of the Board
  • Morton F. Goldberg, MD, Director
  • Praveen Tyle, PhD, Director
  • Thomas Balland, Director
  • Thomas E. Hancock, Director
  • Bernard Malfroy-Camine, PhD, Director
  • Mounia Chaoui, PhD, Director

Last updated: 2024-12-31

IRIDEX Corporation

IRIDEX Corporation logo
Market Cap: Lowest
Employees: Low

Cyclo G6 laser system, IQ 532, and IQ 577 laser photocoagulation systems

IRIDEX Corporation is an ophthalmic medical technology company offering laser systems and devices for the treatment of sight-threatening eye diseases like glaucoma, diabetic macular edema, and retinal diseases.

Tags: diabetic macular edema, eye diseases, glaucoma treatment, medical lasers, ophthalmic technology, retinal diseases

Symbol: IRIX

Recent Price: $1.74

Industry: Medical - Devices

CEO: Mr. Patrick Mercer

Sector: Healthcare

Employees: 111

Address: 1212 Terra Bella Avenue, Mountain View, CA 94043

Phone: 650 940 4700

Last updated: 2024-12-31

iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

inupadenant, EOS-448

Iteos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics. Their product pipeline includes inupadenant and EOS-448, which are in various phases of clinical trials.

Tags: biopharmaceutical, clinical trials, immuno-oncology, therapeutics

Symbol: ITOS

Recent Price: $7.29

Industry: Biotechnology

CEO: Dr. Michel Detheux Ph.D.

Sector: Healthcare

Employees: 157

Address: 321 Arsenal Street, Cambridge, MA 02472-5710

Phone: 339 217 0161

Leadership

  • Michel DETHEUX, President, Chief Executive Officer
  • Matt CALL, Chief Operating Officer
  • Matthew GALL, Chief Financial Officer
  • Yvonne MCGRATH, Chief Scientific Officer
  • David Feltquate, Chief Medical Officer
  • Philippe BRANTEGEM, Executive Vice President of Human Resources
  • Adi OSOVSKY, Executive Vice President of Legal
  • David HALLAL, Chair of the Board
  • Aaron DAVIS,
  • Jill DESIMONE,
  • David LEE,
  • Tim VAN HAUWERMEIREN,
  • Tony HO,
  • Robert IANNONE,
  • Ann RHOADS,

Last updated: 2024-12-31

Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KPI-012, EYSUVIS, INVELTYS

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases using proprietary mucus penetrating particles technology.

Tags: biopharmaceutical, corneal epithelial defects, dry eye disease, eye diseases, gene expression, mucus penetrating particles, ocular surgery, retinal diseases

Symbol: KALA

Recent Price: $6.87

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Mark T. Iwicki

Sector: Healthcare

Employees: 43

Address: 1167 Massachusetts Avenue, Arlington, MA 02476

Phone: 781 996 5252

Last updated: 2024-12-31

Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KIO-301

Kiora Pharmaceuticals, Inc. develops therapies for ophthalmic diseases, with lead product KIO-301 in Phase 1 trial for vision restoration in degenerative retinal diseases and other products in trials for conditions like rheumatoid arthritis-related ocular issues and corneal wound repair.

Tags: clinical trials, ophthalmic diseases, ophthalmology, pharmaceuticals, vision restoration

Symbol: KPRX

Recent Price: $3.30

Industry: Biotechnology

CEO: Dr. Brian M. Strem Ph.D.

Sector: Healthcare

Employees: 12

Address: 1371 East 2100 South, Salt Lake City, UT 84105

Phone: 781 788 8869

Last updated: 2024-12-31

Ocugen, Inc.

Ocugen, Inc. logo
Market Cap: Low
Employees: Low

OCU400, OCU410, OCU200

Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies to cure blindness diseases. Its product pipeline includes gene therapy candidates targeting various retinal diseases and other conditions.

Tags: biopharmaceutical, blindness diseases, gene therapy, retinal diseases, strategic partnership

Symbol: OCGN

Recent Price: $0.81

Industry: Biotechnology

CEO: Dr. Shankar Musunuri M.B.A., Ph.D.

Sector: Healthcare

Employees: 65

Address: 263 Great Valley Parkway, Malvern, PA 19355

Phone: 484 328 4701

Last updated: 2024-12-31

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. logo
Market Cap: High
Employees: Low

Re Sure Sealant; DEXTENZA; OTX-TKI; OTX-TIC; OTX-CSI

Ocular Therapeutix is a biopharmaceutical company that develops and commercializes therapies for eye diseases using bioresorbable hydrogel-based technology, offering products like Re Sure Sealant and DEXTENZA.

Tags: biopharmaceutical, eye care, hydrogel, ophthalmic devices, ophthalmology, therapy

Symbol: OCUL

Recent Price: $8.35

Industry: Biotechnology

CEO: Dr. Pravin U. Dugel M.D.

Sector: Healthcare

Employees: 267

Address: 24 Crosby Drive, Bedford, MA 01730

Phone: 781 357 4000

Leadership

  • Pravin U. Dugel, MD, Executive Chairman, President and CEO
  • Karen-Leigh Edwards, PhD, MBA, Chief Operations Officer
  • Peter Jarrett, PhD, Chief Technical Officer
  • Donald Notman, Chief Financial Officer and Chief Operating Officer
  • Nadia K. Waheed, MD, MPH, Chief Medical Officer
  • Jeffrey S. Heier, MD, Chief Scientific Officer
  • Steve Meyers, Chief Commercial Officer
  • Tracy Smith, Vice President, Human Resources
  • Sanjay Nayak, MBBS, PhD, Chief Strategy Officer
  • Peter K. Kaiser, MD, Chief Development Officer
  • Todd Anderman, JD, Chief Legal Officer and Corporate Secretary
  • Charles Warden, Lead Independent Director
  • Adrienne Graves, PhD, Director
  • Leslie Williams, Director
  • Richard Lindstrom, MD, Director
  • Seung Suh Hong, PhD, Director
  • Merilee Raines, Director

Last updated: 2024-12-31

RxSight, Inc.

RxSight, Inc. logo
Market Cap: High
Employees: Medium

Rx Sight system

Rx Sight, Inc. is a medical technology company specializing in light adjustable intraocular lenses used in cataract surgery, allowing for post-operative customization of visual acuity.

Tags: Rx Sight system, cataract surgery, intraocular lenses, medical technology, visual acuity

Symbol: RXST

Recent Price: $33.81

Industry: Medical - Devices

CEO: Dr. Ronald M. Kurtz M.D.

Sector: Healthcare

Employees: 374

Address: 100 Columbia, Aliso Viejo, CA 92656

Phone: 949 521 7830

Last updated: 2024-12-31

scPharmaceuticals Inc.

scPharmaceuticals Inc. logo
Market Cap: Low
Employees: Low

FUROSCIX

sc Pharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing pharmaceutical products, with a lead product candidate, FUROSCIX, aimed at treating congestion in heart failure patients using an on-body infusor.

Tags: antibiotics, drug development, healthcare, heart failure, pharmaceuticals

Symbol: SCPH

Recent Price: $3.50

Industry: Biotechnology

CEO: Mr. John H. Tucker

Sector: Healthcare

Employees: 135

Address: 2400 District Avenue, Burlington, MA 01803

Phone: 617 517 0730

Leadership

  • John H. Tucker, President and Chief Executive Officer
  • Rachael Nokes, Chief Financial Officer
  • Mike Hassman, Senior Vice President, Technical Operations
  • John Mohr, Pharm.D., FIDP, Senior Vice President, Clinical Development and Medical Affairs
  • William T. Abraham, MD,
  • Mette Kirstine Agger, Co-Founder & CEO, 7TM Pharma A/S
  • Minnie V. Baylor-Henry, President, B-Henry & Associates
  • Sara Bonstein, CFO, Insmed Incorporated
  • Frederick Hudson, Former Partner in Charge of KPMG’s Largest Healthcare Industry Audit Practice Located in the Mid-Atlantic Region
  • Jack A. Khattar, Founder, President & Chief Executive Officer, Supernus Pharmaceuticals
  • Leonard D. Schaeffer, Founding Chairman & CEO, Wellpoint
  • Klaus Veitinger, MD, PhD, Venture Partner, Orbimed
  • Dan Bensimhon, MD, Medical Director Advanced Heart Failure & Mechanical Circulatory Support Program, Cone Health, Greensboro, NC
  • G. Michael Felker, MD, Chief, Heart Failure Service, Division of Cardiology, Duke University School of Medicine
  • Marv Konstam, MD, Professor of Medicine, Tufts University School of Medicine, Chief Physician Executive of the Cardiovascular Center at Tufts Medical Center
  • W. Frank Peacock, MD, FACEP, FACC, FESC, Professor, Vice Chair of Research, Department of Emergency Medicine, Baylor College of Medicine, Ben Taub General Hospital
  • Stuart Russell, MD, Regional Director of Heart Failure Program, Duke University School of Medicine
  • James E. Udelson, MD, Chief, Division of Cardiology, Tufts Medical Center, Professor of Medicine and Radiology Tufts University School of Medicine
  • William Weintraub, MD, Director of Outcomes Research, MedStar Heart and Vascular Institute

Last updated: 2024-12-31

Scopus BioPharma Inc.

Scopus BioPharma Inc. logo
Market Cap: Lowest
Employees: Lowest

Duet Platform

Scopus Bio Pharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics for serious diseases with lead programs in immuno-oncology gene therapy.

Tags: biopharmaceutical, cancer treatment, gene therapy, immuno-oncology, therapeutics

Symbol: SCPS

Recent Price: $0.00

Industry: Biotechnology

CEO: Dr. Alan D. Horsager Ph.D.

Sector: Healthcare

Employees: 13

Address: 420 Lexington Avenue, New York, NY 10170

Phone: 212 479 2513

Last updated: 2024-12-31

STAAR Surgical Company

STAAR Surgical Company logo
Market Cap: High
Employees: Medium

Visian Implantable Collamer Lenses (ICLs)

STAAR Surgical Company, along with its subsidiaries, designs and sells implantable lenses for treating visual disorders like myopia, hyperopia, astigmatism, and presbyopia. They also offer solutions for cataract surgery, marketing primarily to healthcare providers worldwide.

Tags: cataract surgery, implantable lenses, medical devices, ophthalmology, vision care

Symbol: STAA

Recent Price: $24.08

Industry: Medical - Instruments & Supplies

CEO: Mr. Thomas G. Frinzi

Sector: Healthcare

Employees: 1056

Address: 25651 Atlantic Ocean Drive, Lake Forest, CA 92630

Phone: 626 303 7902

Last updated: 2024-12-31

Globus Medical, Inc.

Globus Medical, Inc. logo
Market Cap: Highest
Employees: High

Healthcare Solutions

Globus Medical, Inc. develops and commercializes healthcare solutions for musculoskeletal disorders, offering spine products, motion preservation technologies, and treatment for orthopedic trauma among others.

Tags: healthcare, medical devices, orthopedic trauma, regenerative biologics, spine products

Symbol: GMED

Recent Price: $82.67

Industry: Medical - Devices

CEO: Mr. Daniel T. Scavilla

Sector: Healthcare

Employees: 5000

Address: 2560 General Armistead Avenue, Audubon, PA 19403

Phone: 610 930 1800

Last updated: 2024-12-31

LENSAR, Inc.

LENSAR, Inc. logo
Market Cap: Lowest
Employees: Low

LENSAR Laser System

LENSAR, Inc. is a commercial-stage medical device company specializing in the design, development, and marketing of a femtosecond laser system for cataract treatment and corneal astigmatism management.

Tags: cataract treatment, corneal astigmatism, healthcare technology, laser system, medical device

Symbol: LNSR

Recent Price: $8.66

Industry: Medical - Devices

CEO: Mr. Nicholas T. Curtis

Sector: Healthcare

Employees: 130

Address: 2800 Discovery Drive, Orlando, FL 32826

Phone: 888 536 7271

Last updated: 2024-12-31

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

STK-001, STK-002

Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing antisense oligonucleotide medicines to treat genetic diseases. Their lead product, STK-001, is aimed at treating Dravet syndrome, while STK-002 targets autosomal dominant optic atrophy.

Tags: Dravet syndrome, antisense oligonucleotides, biopharmaceutical, epilepsy, genetic diseases, genetic medicine

Symbol: STOK

Recent Price: $10.80

Industry: Biotechnology

CEO: Dr. Edward M. Kaye M.D., Ph.D.

Sector: Healthcare

Employees: 110

Address: 45 Wiggins Avenue, Bedford, MA 01730

Phone: 781 430 8200

Leadership

  • Edward M. Kaye, M.D., Chief Executive Officer & Director
  • Jonathan Allan, J.D., General Counsel
  • Isabel Aznarez, Ph.D., Senior Vice President, Discovery Research and Co-Founder
  • Jason Hoitt, Chief Commercial Officer
  • Dawn Kalmar, Chief Communications Officer
  • Tommy Leggett, Chief Financial Officer
  • Shamim Ruff, Chief Regulatory Officer
  • Barry S. Ticho, M.D., Ph.D., FACC, Chief Medical Officer
  • Joan Wood, Chief Human Resources Officer
  • Adrian Krainer, Ph.D., Co-founder & Director
  • Arthur Tzianabos, Ph.D., Chairman
  • Jennifer Burstein, MBA, CPA, Director
  • Seth L. Harrison, M.D., Director
  • Arthur Levin, Ph.D., Director
  • Garry E. Menzel, Ph.D., MBA, Director
  • Ian F. Smith, Director
  • Julie Anne Smith, Director

Last updated: 2024-12-31